Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Bristol-Myers And Vanderbilt Team Up

by Lisa M. Jarvis
October 1, 2012 | A version of this story appeared in Volume 90, Issue 40

Bristol-Myers Squibb has teamed with the Vanderbilt Center for Neuroscience Drug Discovery to develop new drugs for the treatment of Parkinson’s disease. The Vanderbilt center, supported by funding from the Michael J. Fox Foundation, has discovered positive allosteric modulators of the mGluR4 glutamate receptor. Drug candidates will be identified from that program, and BMS will have the right to further develop them. As part of the pact, Vanderbilt University will receive an undisclosed up-front fee and several years of research funding for the discovery of other compounds.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.